Phreesia initiated with an Outperform at Mizuho

Mizuho initiated coverage of Phreesia (PHR) with an Outperform rating and $36 price target Phreesia is a leader in patient intake management software for practitioners, the analyst tells investors in a research note. The firm likes the company’s ability to monetize its solutions via pharma digital marketing spend and is encouraged by the continued growth in its average healthcare services clients.